Phase II Study of Personalized Natural Killer Cell Therapy After Chemotherapy and Umbilical Cord Blood Transplant for Blood Cancers

What this Trial Is About

Researchers are evaluating personalized natural killer NK cell therapy following chemotherapy and umbilical cord blood transplant in patients with various blood cancers, including myelodysplastic syndrome, leukemia, lymphoma, and multiple myeloma. This phase II trial studies how well this therapy works to target remaining tumor cells and reduce the risk of graft versus host disease after transplant. The study also tests selection of cord blood based on specific immune system markers to improve treatment outcomes. Patients receive one of three preparative chemotherapy regimens before undergoing umbilical cord blood transplantation. These regimens vary in intensity and include treatments with drugs such as anti-thymocyte globulin, fludarabine phosphate, busulfan, cyclophosphamide, melphalan, and radiation therapy. Between 30 and 180 days after transplant, participants receive an infusion of NK cells intravenously. The trial follows patients closely after treatment with scheduled visits up to four years. During the study, participants undergo regular assessments including survival monitoring, transplant-related mortality, graft versus host disease, and infection rates. Follow-up visits occur frequently in the first months and then yearly for up to four years. Researchers collect data on progression-free survival and overall survival, aiming to understand how this personalized NK cell therapy performs after transplant for blood cancers.

Personalized NK Cell Therapy in CBT